Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Echinococcus granulosus | tar DNA binding protein | 0.0062 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0.1896 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.002 | 0.1244 | 0.656 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.1896 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.1896 | 1 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.1896 | 0.0745 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.1896 | 0.5 |
Trypanosoma brucei | unspecified product | 0.002 | 0.1244 | 0.656 |
Schistosoma mansoni | tar DNA-binding protein | 0.0062 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0062 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 0.1244 | 0.656 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.1896 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 0.1244 | 0.656 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Echinococcus multilocularis | tar DNA binding protein | 0.0062 | 1 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.1896 | 0.5 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.1896 | 0.0745 |
Brugia malayi | TAR-binding protein | 0.0062 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.1896 | 0.0745 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0.1896 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.1896 | 0.0745 |
Schistosoma mansoni | tar DNA-binding protein | 0.0062 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0062 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0062 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0062 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0062 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.1896 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0062 | 1 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.1896 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.1896 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.1896 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.1896 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.1896 | 0.0745 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0.1244 | 0.656 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.1896 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0062 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0.1896 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 0.1244 | 0.656 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.1896 | 1 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0023 | 0.1896 | 0.0745 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.6834 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.3753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.